Shares of Strides Pharma Science climbed more than 4% on the NSE on Thursday, reacting positively to the company’s strong Q3 earnings performance, led by a sharp rise in profitability and margin expansion.
The pharmaceutical company reported a net profit of Rs 202 crore for the third quarter, compared with Rs 88 crore in the same period last year, marking a year-on-year jump of nearly 130%. The strong profit growth was driven by improved operating leverage and better efficiency across key business segments.
Revenue for the quarter came in at Rs 1,194.6 crore, up 3.6% year-on-year from Rs 1,153.6 crore in Q3 of the previous financial year. While topline growth remained modest, steady demand in regulated markets and portfolio optimisation helped support overall revenue performance.
Operating metrics also showed improvement. EBITDA increased 12.2% YoY to Rs 235.8 crore, compared with Rs 210.2 crore a year ago. EBITDA margin expanded to 19.7%, up from 18.2% in the corresponding quarter last year, reflecting tighter cost controls and improved operating efficiency.
Following the results, Strides Pharma Science shares were trading around Rs 843.55, up 4.17%, adding Rs 33.80 in Thursday’s session, as investors welcomed the strong earnings momentum.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
